


Curriculum Vitae

Name	Sooheon Lee	
Current Position & Affiliation	Assistant Professor Korea University Anam Hospital	
Country	Republic of Korea	

Educational Background

Sungkyunkwan University College of Medicine, Seoul, Korea	Ph.D.	2012
Yonsei University College of Medicine, Seoul, Korea	M.D.	2004
Seoul National University College of Social Sciences, Korea	Ph.D	2000 candidate

Professional Experience

2019.03 ~	Assistant Professor, Div. Oncology-Hematology, Dep. Internal Medicine, Korea University Anam Hospital
2018.11 ~ 2019.02	Medical Director, Cellgene Korea
2014.03 ~ 2018.10	Medical Director, Pfizer Korea
2011.03 ~ 2014.02	Assistant Professor, Div. Medical Oncology, Dep. Internal Medicine, Severance Hospital, Yonsei University
2010.03 ~ 2011.02	Clinical Research Professor, Div. Medical Oncology, Dep. Internal Medicine, Severance Hospital, Yonsei University
2009.03 ~ 2010.02	Clinical fellow, Div. Oncology-Hematology, Dep. Internal Medicine, Samsung Medical Center
2005.03 ~ 2009.02	Internal Medicine Resident, Severance Hospital, Yonsei University
2004.03 ~ 2005.02	Intern, Severance Hospital, Yonsei University

Professional Organizations

2007 ~ Korean Cancer Study Group
 2008 ~ Korean Society of Medical Oncology
 2008 ~ The Korean Cancer Association

Main Scientific Publications

1. **Lee S**, Park YS, Chang WJ, Choi JY, Lim A, Kim B, Lee SB, Lee JW, Kim SH, Kim J, Kwak JM, Yoon KC, Lee SH, Kim YH. Clinical implication of liquid biopsy in colorectal cancer patients treated with metastasectomy. *Cancers*, 2021;13(9), 2231. doi: 10.3390/cancers13092231
2. **Lee S**, Kim D, Youk T, Hong S, Incidence and Clinical Outcomes of Febrile Neutropenia in Adult Cancer Patients with Chemotherapy Using Korean Nationwide Health Insurance Database, *Yonsei Med J*, 2021 Jun;62(6):479-486. doi.org/10.3349/ymj.2021.62.6.479
3. **Lee S**, Im SA, Kim GM, Jung KH, Kang SY, Park IH, Kim JH, Lee KE, Ahn H, Lee MH, Kim HJ, Kim HJ, Lee JI, Koh SJ, Park YH. Patient-reported outcomes palbociclib plus exemestane with GnRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer from the YoungPearl phase II trial (KCSG-BR 15-10). *Cancers* 2020 Nov 5;12(11): 3265.
4. Kang HJ & **Lee S**. Tolerability of alternative dosing schedules for Sunitinib: a systematic review and meta-analysis. *Yonsei Med J*. 2020 Oct;61(1):837.
5. **Lee S**, Lee YW, Sung JS, Chung HJ, Lim AR, Kim JW, Choi YJ, Park KH, Kim YH. Clinical application of targeted deep sequencing in metastatic colorectal cancer patients: actionable genomic alteration in K-MASTER project. *Cancer R Treat*. 2021 Jan;53(1):123.
6. **Lee S**, Lim AR, Kim MJ, Choi YJ, Kim JW, Park KH, Shin SW, Kim YH. Innovative countermeasures can maintain cancer care continuity during the coronavirus disease-2019 pandemic in Korea. *Eur J Cancer*. 2020 Sep;136:69.